Hepatic Encephalopathy
Hepatic encephalopathy (HE) is a neuropsychiatric syndrome caused by liver dysfunction and portal hypertension. It occurs when toxins normally cleared by the liver accumulate and affect brain function. Symptoms range from subtle cognitive changes to coma. HE incorporates both impaired hepatic detoxification and altered cerebral neurotransmission. Understanding its mechanisms explains why it fluctuates and why seemingly minor triggers can cause rapid deterioration.
What You Need to Know
Hepatic encephalopathy is a neuropsychiatric complication of liver disease that arises when the liver can no longer effectively clear neurotoxins from the circulation. Reduced hepatocellular function limits normal detoxification processes, while portal hypertension promotes the development of portosystemic shunts that allow blood from the gut to bypass the liver altogether. As a result, substances that are normally metabolised by the liver enter the systemic circulation and reach the brain. Although ammonia is the most widely recognised toxin, hepatic encephalopathy is a multifactorial condition involving several metabolic and inflammatory contributors.
Ammonia is primarily produced in the gut through the breakdown of dietary protein and the action of intestinal bacteria. In the setting of liver disease, ammonia crosses the blood–brain barrier and is taken up by astrocytes, the supporting cells of the central nervous system. Within astrocytes, ammonia is converted to glutamine, which increases intracellular osmotic pressure and leads to cellular swelling. This disrupts normal neuronal signalling and cerebral energy metabolism, producing a spectrum of neurological changes that can range from subtle cognitive impairment to coma.
Several interacting processes contribute to the development and progression of hepatic encephalopathy:
accumulation of ammonia and other gut-derived neurotoxins due to reduced hepatic clearance
portosystemic shunting that bypasses hepatic metabolism and increases systemic toxin exposure
astrocyte dysfunction and cerebral oedema that impair neurotransmission and brain function
Alcohol plays a significant role by accelerating liver injury and amplifying toxin production. Chronic alcohol use worsens hepatic inflammation and fibrosis, further reducing detoxification capacity, and alters gut permeability and microbiota, increasing ammonia generation within the intestine. Continued alcohol intake is strongly associated with more frequent and more severe episodes of hepatic encephalopathy, while abstinence reduces recurrence and supports neurological recovery over time.
Beyond the Basics
Portosystemic shunting and toxin bypass
Portal hypertension alters normal blood flow through the liver by diverting blood into collateral vessels that connect the portal and systemic circulations. While this diversion reduces pressure within the portal system, it also allows blood from the gastrointestinal tract to bypass hepatic detoxification pathways. As a result, ammonia and other gut-derived neurotoxins enter the systemic circulation at higher concentrations than would normally occur. This mechanism explains why hepatic encephalopathy can develop even when standard liver function tests appear relatively stable, as toxin exposure is driven by altered blood flow rather than hepatocyte failure alone.
The degree of portosystemic shunting varies between individuals and increases as portal hypertension worsens. Large spontaneous shunts or surgically created shunts can markedly increase toxin delivery to the brain. In these settings, hepatic encephalopathy may become recurrent or persistent despite relatively preserved synthetic liver function, highlighting the importance of haemodynamic changes in disease expression.
Astrocyte dysfunction and cerebral oedema
Astrocytes are specialised glial cells that support neuronal function and regulate the brain’s metabolic environment. They play a central role in ammonia handling within the central nervous system. Excess ammonia that crosses the blood–brain barrier is taken up by astrocytes and converted to glutamine, an osmotically active amino acid. The accumulation of glutamine increases intracellular osmotic pressure, drawing water into the cell and causing astrocyte swelling.
Astrocyte swelling disrupts normal neuronal signalling and interferes with regulation of cerebral blood flow and neurotransmitter balance. In severe cases, particularly in acute liver failure, widespread astrocyte swelling contributes to cerebral oedema and raised intracranial pressure. Even in chronic liver disease, more subtle astrocyte dysfunction is sufficient to impair cognition, attention, and motor control.
Neurotransmitter imbalance
Hepatic encephalopathy is characterised by altered neurotransmission within the brain, particularly an increase in inhibitory signalling. Gamma-aminobutyric acid, the main inhibitory neurotransmitter in the central nervous system, has increased activity in hepatic encephalopathy. This heightened inhibitory tone reduces neuronal excitability and slows cortical processing, contributing to drowsiness, impaired concentration, and reduced responsiveness.
At the same time, excitatory neurotransmission is diminished due to altered glutamate handling and disrupted synaptic function. The combined effect of increased inhibition and reduced excitation creates an imbalance that manifests clinically as cognitive slowing, impaired coordination, and changes in behaviour. These changes often fluctuate, which explains the variable and episodic nature of hepatic encephalopathy symptoms.
Systemic inflammation and precipitating factors
Systemic inflammation plays an important role in triggering episodes of hepatic encephalopathy. Inflammatory states increase blood–brain barrier permeability and amplify the neurotoxic effects of ammonia. Common precipitants include infection, gastrointestinal bleeding, electrolyte disturbances, constipation, dehydration, and renal dysfunction. Each of these factors either increases ammonia production in the gut or reduces its clearance from the circulation.
The interaction between inflammation and ammonia explains why hepatic encephalopathy often develops acutely in people with chronic liver disease who have been previously stable. Identifying and correcting precipitating factors is therefore central to management, as resolution of the trigger often leads to significant neurological improvement.
Alcohol and recurrent encephalopathy
Alcohol exacerbates hepatic encephalopathy through multiple pathways. Ongoing alcohol use accelerates liver injury, worsening portal hypertension and reducing detoxification capacity. It also alters gut permeability and microbiota, increasing the generation of ammonia and other neurotoxins within the intestine. In addition, alcohol contributes to malnutrition and muscle wasting, reducing skeletal muscle’s role in ammonia buffering through extrahepatic metabolism.
Continued alcohol intake is strongly associated with more frequent, more severe, and more persistent episodes of hepatic encephalopathy. In contrast, sustained abstinence improves metabolic stability, reduces toxin load, and is associated with fewer episodes and improved neurological recovery over time.
Clinical Connections
Hepatic encephalopathy commonly presents with a spectrum of neurocognitive changes, ranging from subtle alterations in attention and sleep–wake patterns to confusion, disorientation, and reduced level of consciousness. Early features may include irritability, slowed thinking, or reversal of normal sleep patterns, while more advanced episodes can progress to stupor or coma. Asterixis, a flapping tremor caused by impaired motor control, is a classic sign in moderate disease but may be absent in severe encephalopathy when voluntary movement is markedly reduced. Episodes are frequently precipitated by identifiable stressors that increase toxin load or reduce clearance, which explains the often abrupt deterioration seen in people with chronic liver disease.
Assessment focuses on recognising both overt and evolving changes, as recurrent episodes are associated with cumulative cognitive impairment and functional decline. Diagnosis is clinical and based on characteristic neurological changes in the context of liver disease, after exclusion of alternative causes such as stroke, intracranial infection, or drug toxicity. While ammonia levels may support the diagnosis, they do not reliably correlate with severity and should be interpreted in conjunction with the clinical picture.
Key features that raise concern for an evolving episode include:
new or worsening confusion, altered behaviour, or changes in sleep pattern
motor signs such as asterixis, unsteady gait, or slowed movements
evidence of common precipitants, including infection, gastrointestinal bleeding, dehydration, or electrolyte disturbance
Recurrent hepatic encephalopathy has a substantial impact beyond the acute episode. Frequent relapses interfere with independence, driving, employment, and medication adherence, and place significant strain on family members and caregivers. Long-term management therefore prioritises prevention through identification and treatment of precipitating factors, optimisation of therapies that reduce ammonia production or absorption, and regular follow-up to detect early cognitive change. Clear education for patients and families about early warning signs, adherence to treatment, and when to seek medical review is central to reducing recurrence and improving quality of life.
Concept Check
Why does portal hypertension contribute to hepatic encephalopathy?
How does ammonia affect astrocyte function?
Why can HE worsen suddenly despite stable liver disease?
What role does systemic inflammation play in HE?
How does alcohol increase the risk of recurrent encephalopathy?